Iduronate 2 Sulfatase Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Iduronate 2 Sulfatase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Iduronate 2 Sulfatase pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Iduronate 2 Sulfatase Development are AngioChem Inc, ArmaGen Inc, Bioasis Technologies Inc, Green Cross Corp, JCR Pharmaceuticals Co Ltd, Laboratorios Del Dr Esteve SA, RegenxBio Inc, Sangamo Therapeutics Inc, Shire Plc
The Iduronate 2 Sulfatase pipeline guide also reviews of key players involved in therapeutic development for Iduronate 2 Sulfatase and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.
Sample copy is available at: https://www.marketinsightsreports.com/reports/062215775/iduronate-2-sulfatase-alpha-l-iduronate-sulfate-sulfatase-or-idursulfase-or-ids-or-ec-3-1-6-13-pipeline-review-h1-2017/inquiry
Scope of this report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Iduronate 2 Sulfatase. The pipeline guide reviews pipeline therapeutics for Iduronate 2 Sulfatase by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iduronate 2 Sulfatase therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Iduronate 2 Sulfatase therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Iduronate 2 Sulfatase.
- This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iduronate 2 Sulfatase. Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 22.214.171.124) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Iduronate 2 Sulfatase – Pipeline Review, H1 2017, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 188.8.131.52) – Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.
Furthermore, this report also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.